Low affordability may limit the effect of cervical cancer vaccination in Central and Eastern European countries [6]

Journal of Clinical Oncology

Volumn 25, Issue 34, 2007, Pages 5534-5537

  Zubor, Pavol ^a   Danko, Jan ^a   Kajo, Karol ^a   Szunyogh, Norbert ^b  

^a University Teaching Hospital in Martin   (Slovakia)

^b St Lukas Hospital   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADENOCARCINOMA; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER SCREENING; COLPOSCOPY; CONDYLOMA; COST BENEFIT ANALYSIS; CYTOLOGY; DRUG EFFICACY; DRUG SAFETY; EASTERN EUROPE; HEALTH CARE ACCESS; HEALTH CARE NEED; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; LETTER; PAPANICOLAOU TEST; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; WART VIRUS;

ALPHAPAPILLOMAVIRUS; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SLOVAKIA; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 36849085310     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.3792     Document Type: Letter

References (12)

1. Chan JK, Berek JS: Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 25:2975-2982, 2007
2. Ferlay J, Bray F, Pisani P, et al: GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0. Lyon, France, IARC Press, 2004
3. Arbyn M, Raifu A, Autier P, et al: Burden of cervical cancer in Europe: Estimates for 2004. Ann Oncol 18:1708-1715, 2007
4. Ondrusova M, Plesko I, Safaei Diba CH, et al: Cancer Incidence in the Slovak Republic 2003. Bratislava, National Health Information Centre, 2006
5. IARC Working Group.Human papillomaviruses. IARC Monographs on the evaluation of carcinogenic risks to humans, vol. 64. Lyon, France, International Agency for Research on Cancer, 1995
6. Ault KA: Future II Study Group: Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet 369:1861-1868, 2007
7. Paavonen J, Jenkins D, Bosch FX, et al: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161-2170, 2007
8. Joura EA, Leodolter S, Hernandez-Avila M, et al: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three randomised clinical trials. Lancet 369:1693-1702, 2007
9. Kahn JA, Lan D, Kahn RS: Sociodemographic factors associated with high-risk human papillomavirus infection. Obstet Gynecol 110:87-95, 2007
10. US Food and Drug Administration.FDA briefing information on HPV vaccine. Rockville, MD, Vaccines and Related Biological Products Advisory Committee, 2006
11. Kahn JA, Burk RD: Papillomavirus vaccines in perspective. Lancet 369:2135-2137, 2007
12. World Health Organization Regional Office for Europe: European health for all database (HFA-DB). http://data.euro.who.int/hfadb/